Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07093775

Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score

Prognostic Implication of Tumor Grade in Patients With Node-negative Breast Cancer Aged ≤ 50 Years With 21-gene Recurrence Scores of 11-25

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
4,000 (estimated)
Sponsor
Gangnam Severance Hospital · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.

Conditions

Interventions

TypeNameDescription
OTHERTumor grade (I or II vs. III)We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score

Timeline

Start date
2025-07-01
Primary completion
2025-12-01
Completion
2026-03-01
First posted
2025-07-30
Last updated
2025-07-30

Source: ClinicalTrials.gov record NCT07093775. Inclusion in this directory is not an endorsement.

Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score (NCT07093775) · Clinical Trials Directory